Français

Menu

Close

ABOUT ATTR-CM
WHEN TO SUSPECT
How ATTR-CM is diagnosed
TALK TO YOUR DOCTOR
HEART TALKS: PATIENT STORIES
Educational resources
FOR CAREGIVERS

ATTR-CM is a serious, underrecognized, and underdiagnosed type of amyloidosis that affects the heart and is associated with heart failure.

SEE WHAT HAPPENS INSIDE YOUR BODY WHEN YOU HAVE ATTR-CM

Watch the video or scroll down to learn more.

The liver produces transthyretin, a transport protein that carries the hormone thyroxine and vitamin A (retinol) throughout the bloodstream.

When someone has ATTR-CM, either due to aging (wild-type) or an inherited genetic variant (hereditary), the protein becomes unstable and misfolds.

Over time, the misfolded proteins join together and build up in the body, including in the heart (causing the heart muscle to thicken and stiffen, eventually leading to heart failure).

There Are 2 types of ATTR-CM
Wild-type ATTR-CM (wtATTR):
  • Associated with aging
  • Most often affects men over the age of 60
  • May be the most common form of ATTR-CM

Hereditary ATTR-CM (hATTR-CM):
  • Caused by a change (or “mutation”) in one of your genes
  • Passed down from a relative
  • Affects both men and women, with symptoms beginning at different ages
  • There are numerous known mutations that cause hATTR-CM; the most common mutations in North America include Val122Ile (West African descent), Thr60Ala (Northern Irish descent), and Val30Met (Swedish, Portuguese, Japanese descent)

hATTR-CM IS PASSED DOWN FROM A RELATIVE AND IS CAUSED BY A CHANGE (OR “MUTATION”) IN ONE OF YOUR GENES.

TELL YOUR DOCTOR IF YOU HAVE A FAMILY HISTORY OF ATTR-CM AND/OR UNRESOLVED HEART FAILURE.

ATTR-CM could be the underlying cause of your heart failure, so it’s
important to recognize the messages your heart may be sending.

NEXT: When to SuspectLoading

Brought to you by one of Canada’s leading research-based pharmaceutical companies

This site is intended only for Canadian residents. The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.
© 2023 All rights reserved.

PP-VDM-CAN-0055-EN